Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Visa Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $103.96 (market cap $8.48B), while Visa Inc trades at $395.03 (market cap $743.55B). The key difference: Visa Inc is far larger — about 87.7× Hinge Health Inc. Class A Common Stock's market cap, and Visa Inc pays a 0.68% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Visa Inc for 115 Days on average.
| HNGE | V | |
|---|---|---|
Market Cap | $8.48B | $743.55B |
Volume | 879,799 | 7,478,804 |
Sector | Health | Financials |
52-Week High | $105.14 | $396.06 |
52-Week Low | $31.17 | $295.52 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $8.10B | $754.13B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Visa (V) trades at $396.06, up 1.74% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and key resistance at $399. Fundamentally, Visa reported robust earnings beats in recent quarters, with Q2 2026 results due April 28. Revenue grew to $40B in 2025, with a net income margin of 50.78%, though the P/E ratio of 33.71 is elevated. Recent news highlights Visa's push into AI-driven commerce and stablecoin partnerships.
Outlook remains positive with 85% analyst buy ratings and a $423.29 consensus target, implying 7% upside. Risks include competitive fintech threats and regulatory scrutiny. Strong cash flow and institutional accumulation support long-term growth, but high valuation requires sustained execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
